Physician profile
Aeree Yoon
NPI 1679574206
$8,954.27
in general payments reported to CMS, 2019-2025
23 companies · $2,218 in 2025
The $2,218 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,898 · 2020: $276 · 2021: $1,274 · 2022: $1,709 · 2023: $1,051 · 2024: $527 · 2025: $2,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,796.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,666.58 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,107.24 | 2019-2025 | Mounjaro |
| Janssen Pharmaceuticals, INC | $1,012.86 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $1,012.65 | 2021-2025 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $659.07 | 2021-2023 | |
| Glaxosmithkline, LLC. | $596.87 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Amarin Pharma, INC. | $500.12 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $364.40 | 2021 | |
| Abbvie INC. | $282.52 | 2022-2023 | Ubrelvy, Qulipta |
| Boston Scientific Corporation | $272.38 | 2020-2025 | Farapulse, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $165.07 | 2025 | Freestyle Libre 3 |
| Stryker Corporation | $158.40 | 2025 | Nico Brainpath |
| Teleflex LLC | $154.97 | 2025 | Urolift |
| Insulet Corporation | $149.30 | 2025 | Omnipod |
| Amgen INC. | $125.67 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.48 | 2025 | Caplyta |
| Allergan, INC. | $125.00 | 2019 | |
| Eisai INC. | $124.98 | 2022 | |
| Pfizer INC. | $115.02 | 2025 | |
| Heartflow, INC. | $103.31 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.47 | 2019 | |
| Seqirus USA INC | $20.97 | 2019 | |
| Currax Pharmaceuticals LLC | $13.94 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aeree Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.